Latest Insider Transactions at Adaptive Biotechnologies Corp (ADPT)
This section provides a real-time view of insider transactions for Adaptive Biotechnologies Corp (ADPT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Adaptive Biotechnologies Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Adaptive Biotechnologies Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 04
2022
|
Stacy L Taylor SVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
61,779
+44.58%
|
-
|
|
Mar 04
2022
|
Sharon Benzeno Chief Commercial Ofc Imm Med |
BUY
Grant, award, or other acquisition
|
Direct |
82,372
+43.9%
|
-
|
|
Mar 04
2022
|
Julie Rubinstein President |
BUY
Grant, award, or other acquisition
|
Direct |
185,338
+44.5%
|
-
|
|
Mar 04
2022
|
Nitin Sood Chief Commercial Officer, MRD |
BUY
Grant, award, or other acquisition
|
Direct |
65,898
+28.78%
|
-
|
|
Jan 26
2022
|
Leslie Trigg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+37.53%
|
-
|
|
Jan 26
2022
|
Katey Einterz Owen Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+37.53%
|
-
|
|
Jan 26
2022
|
Peter M Neupert Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Robert Hershberg Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Michelle Renee Griffin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Kevin T Conroy Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 26
2022
|
Michael J Pellini Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,689
+44.95%
|
-
|
|
Jan 07
2022
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,021
-1.97%
|
$23,483
$23.32 P/Share
|
|
Dec 22
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,000
-31.64%
|
$300,000
$30.0 P/Share
|
|
Dec 22
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+24.04%
|
$70,000
$7.27 P/Share
|
|
Dec 22
2021
|
Stacy L Taylor SVP and General Counsel |
SELL
Open market or private sale
|
Direct |
15,338
-50.5%
|
$460,140
$30.0 P/Share
|
|
Dec 22
2021
|
Stacy L Taylor SVP and General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
15,338
+21.67%
|
$107,366
$7.18 P/Share
|
|
Nov 18
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
300
-0.43%
|
$9,300
$31.36 P/Share
|
|
Nov 18
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
300
+0.43%
|
$1,800
$6.55 P/Share
|
|
Nov 17
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,700
-5.06%
|
$118,400
$32.05 P/Share
|
|
Nov 17
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,700
+4.82%
|
$22,200
$6.55 P/Share
|
|
Nov 15
2021
|
Kyle Piskel Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,837
+36.42%
|
-
|
|
Nov 10
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-18.79%
|
$165,000
$33.93 P/Share
|
|
Nov 10
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+15.82%
|
$35,000
$7.27 P/Share
|
|
Nov 09
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-18.79%
|
$180,000
$36.03 P/Share
|
|
Nov 09
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+15.82%
|
$35,000
$7.27 P/Share
|
|
Oct 21
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,700
-5.06%
|
$122,100
$33.73 P/Share
|
|
Oct 21
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,700
+4.82%
|
$22,200
$6.55 P/Share
|
|
Oct 20
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,700
-5.06%
|
$122,100
$33.71 P/Share
|
|
Oct 20
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,700
+4.82%
|
$22,200
$6.55 P/Share
|
|
Oct 19
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,800
-2.61%
|
$125,400
$33.33 P/Share
|
|
Oct 19
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,800
+4.94%
|
$22,800
$6.55 P/Share
|
|
Oct 08
2021
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,801
-3.36%
|
$59,433
$33.67 P/Share
|
|
Oct 08
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-5.32%
|
$124,640
$32.96 P/Share
|
|
Oct 08
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
|
Oct 07
2021
|
R Mark Adams Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,324
-2.41%
|
$42,368
$32.47 P/Share
|
|
Oct 07
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-2.67%
|
$128,535
$33.09 P/Share
|
|
Oct 07
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
|
Oct 06
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-5.32%
|
$124,640
$32.27 P/Share
|
|
Oct 06
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
|
Oct 06
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-18.79%
|
$160,000
$32.3 P/Share
|
|
Oct 06
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+15.82%
|
$35,000
$7.27 P/Share
|
|
Oct 05
2021
|
Chad M Cohen Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-18.79%
|
$160,000
$32.51 P/Share
|
|
Oct 05
2021
|
Chad M Cohen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+15.82%
|
$35,000
$7.27 P/Share
|
|
Sep 15
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-2.68%
|
$140,220
$36.88 P/Share
|
|
Sep 15
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
|
Sep 14
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-2.69%
|
$140,220
$36.93 P/Share
|
|
Sep 14
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
|
Sep 13
2021
|
Harlan S Robins Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,895
-2.68%
|
$144,115
$37.64 P/Share
|
|
Sep 13
2021
|
Harlan S Robins Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,895
+5.05%
|
$23,370
$6.32 P/Share
|
|
Sep 10
2021
|
Chad M Robins CEO and Chairman |
SELL
Open market or private sale
|
Direct |
5,000
-0.15%
|
$190,000
$38.73 P/Share
|